Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse

Abstract

In hepatoblastoma, the RRM2 subunit of ribonucleotide reductase is associated with disease progression, but in response to chemotherapy, subunit switching favours the less active RRM2B subunit which supports hepatoblastoma cell survival and relapse.